Global Glucagon-like peptide-1 (Glp-1) analogs Market 2020 – Hoffmann-La Roche Ltd, GlaxoSmithKline, AstraZeneca, Sanofi, Eli-Lilly cmiorientedblogexplorer.blogspot.com

Glucagon-like peptide-1 (Glp-1) analogs (also known as incretin mimetics) are a relatively new class of injectable drugs indicated for the treatment of type 2 diabetes. The drugs are normally prescribed for patients who have not been able to control their condition with tablet medication. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
Victoza (Liraglutide); taken once daily, Trulicity (Dulaglutide); taken once weekly, Lyxumia (lixisenatide); taken once daily, Byetta (Exenatide); taken twice daily, and Bydureon (Exenatide); taken once weekly are some of the glucagon-like peptide-1 (Glp-1) analogs available in the United Kingdom for type 2 diabetic patients.
Market Dynamics:
Increasing prevalence of diabetes worldwide is expected to propel the growth of the glucagon-like peptide-1 (Glp-1) analogs market. For instance, according to the Centers for Disease Control and Prevention’s National Diabetes Statistics Report (2020), more than 34 million people in the United States have diabetes (around one in ten), and approximately 90-95% of them have type 2 diabetes. Moreover, increasing awareness among physicians regarding benefits of glucagon-like peptide-1 (Glp-1) analogs over conventional anti-diabetic medication is also expected to augment the growth of the glucagon-like peptide-1 (Glp-1) analogs market.

Read more@https://cmiorientedblogexplorer.blogspot.com/2021/02/increasing-prevalence-of-diabetes-type.html